Prescription Dermatology Therapeutics Market by Product Type (Psoriasis Drugs, Acne and Rosacea Drugs, Dermatitis and Seborrhea Drugs, Skin Cancer, and Fungal Infection Drugs) and by Distribution Channel (Mail Order Pharmacies, Retail Pharmacies, and Hospital Pharmacies)-Global Industry Analytics, COVID-19 Business Impact, and Trends, 2017—2024

                                          
Abstract
                    
The report covers a forecast and an analysis of the prescription dermatology therapeutics market on a global and regional level. The study provides historical data from 2015 to 2017 along with a forecast from 2018 to 2024 based on revenue (USD Billion). The study includes drivers and restraints for the prescription dermatology therapeutics market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the prescription dermatology therapeutics market on a global and regional level.

In order to give the users of this report a comprehensive view of the prescription dermatology therapeutics market, we have included a competitive landscape and an analysis of Porter’s Five Forces model. The study encompasses a market attractiveness analysis, wherein all the segments are benchmarked based on their market size, growth rate, and general attractiveness.


The report provides company market share analysis to give a broader overview of the key market players. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product type launch, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the prescription dermatology therapeutics market on a global and regional basis.

The study provides a decisive view of the prescription dermatology therapeutics market by segmenting the market based on product type, distribution channel, and region. The segments have been analyzed based on present and future trends and the market is estimated from 2018 to 2024. By product type, the prescription dermatology therapeutics market includes psoriasis drugs, acne and rosacea drugs, dermatitis and seborrhea drugs, skin cancer, and fungal infection drugs. The distribution channel segment includes mail order pharmacies, retail pharmacies, and hospital pharmacies.

The regional segment includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa with its further divided into major countries, such as the U.S., Canada, Germany, France, UK, China, Japan, India, and Brazil.

The report also includes detailed profiles of various end players, such as Novartis AG, AbbVie, Inc., Amgen, Inc., Janssen Biotech, Inc., Celgene Corporation, Eli Lilly and Company, Pfizer, Inc., Bausch Health Companies, Inc., LEO Pharma A/S, Aurobindo Pharma Ltd., Sun Pharmaceuticals Ltd., and Aclaris Therapeutics, Inc., among others.

This report segments the global prescription dermatology therapeutics market into:

Global Prescription Dermatology Therapeutics Market: By Product Type

	Psoriasis Drugs
	Acne and Rosacea Drugs
	Dermatitis and Seborrhea Drugs
	Skin Cancer
	Fungal Infection Drugs

Global Prescription Dermatology Therapeutics Market: By Distribution Channel

	Mail Order Pharmacies 
	Retail Pharmacies
	Hospital Pharmacies

Key Industry Development

In Aug 2020, LEO Pharma A/S announced the sale of a portfolio of four non-core products to Cheplapharm for EUR 300 million. The agreement represents a milestone in the roll-out of LEO Pharma’s 2030 strategy which increases the company’s focus on new innovative solutions for medical dermatology.
The divested portfolio comprises four products within bone disorders/nephrology, dermatology and gynecology: One-Alpha©(Alfacalcidol), Locoid©(Cortisol), Pimafucin©(Natamycin), and Zineryt©(Erythromycin 40 mg and Zinc Acetate dihydrate). The annual turnover of the portfolio in 2019 amounted to approximately EUR 110 million.
The transaction is expected to close by December 2020, subject to satisfaction of customary closing conditions, including receipt of regulatory approvals. Following the closing, LEO Pharma and Cheplapharm will work closely together to ensure a smooth and effective transition of the products and business.

Global Prescription Dermatology Therapeutics Market: By Region

	North America
	
	The U.S.
	
	Europe
	
	UK
	France
	Germany
		
	Asia Pacific
	
	China
	Japan
	India
	
        Latin America
	Brazil
		
	Middle East and Africa